Clifford Chance

Clifford Chance advises Sirnaomics on its Chapter 18A Hong Kong IPO and listing

Leading international law firm Clifford Chance has advised biotech firm Sirnaomics Ltd's US$63.7 million initial public offering (IPO) and listing on the mainboard of the Hong Kong Stock Exchange.

Sirnaomics is the first company to achieve positive Phase IIa clinical outcomes in oncology for an RNAi therapeutics and the first clinical-stage RNA therapeutics company to have a strong presence in both China and the U.S. The product pipeline of Sirnaomics has over a dozen product candidates for a range of therapeutic indications across rare and large market diseases and its product candidates currently span all stages between preclinical research and IND-enabling studies to Phase I and Phase II clinical trials, creating an extended timeline of product candidates.

The transaction was led by Hong Kong partners Fang Liu and Virginia Lee, supported by a cross-border team from China and the US. Team members include counsel Daryl Fairbairn and associate Jennifer Saionz in New York, senior associate Erxin Lu, associate Ada Zheng and trainee Ruonan Tang in Beijing, counsel Samson Chan and trainee Irene Lau in Shanghai, and associates Jason Liu and Yuan Cao in Hong Kong.

Partner Fang Liu said, "We are pleased to have advised Sirnaomics on this exciting Chapter 18A IPO and listing, being the first RNA therapeutics company to be listed in Hong Kong."